CPHA Canvax
CPHA Canvax
AUDIOVISUAL

"In the US, the first two available Covid-19 vaccines were the ones from Pfizer/BioNTech and Moderna. Both vaccines have very high "efficacy rates," of around 95%. But the third vaccine introduced in the US, from Johnson & Johnson, has a considerably lower efficacy rate: just 66%.

Look at those numbers next to each other, and it's natural to conclude that one of them is considerably worse. Why settle for 66% when you can have 95%? But that isn't the right way to understand a vaccine's efficacy rate, or even to understand what a vaccine does. And public health experts say that if you really want to know which vaccine is the best one, efficacy isn't actually the most important number at all." - Why you can't compare Covid-19 vaccines


Web link

Why you can't compare Covid-19 vaccines

Related Resources

Bookmark

Background Knowledge

Audiovisual

Category

Vaccination Decision Making,Vaccine Safety and Development,Vaccine Hesitancy,Research and Development,Misconceptions,Vaccine Effectiveness and Efficacy,Monitoring and Surveillance,Outbreaks and Pandemics,COVID-19 Vaccination Decision Making
Vaccine Safety and Development
Vaccine Hesitancy
Research and Development
Misconceptions
Vaccine Effectiveness and Efficacy
Monitoring and Surveillance
Outbreaks and Pandemics
COVID-19

0 Comments

Using the comment box below, provide your feedback for this resource. Tell the immunization community how you used the resource, what worked, what didn't and the changes you made. The feedback provided will help inform the immunization community and improve upon the resource made available on CANVax.

All comments are anonymous. Submitted comments will be reviewed for approval by the CANVax team to ensure it meets content submission guidelines. Please note that although CANVax aims to approve comments in a timely manner, volume may result in delays.